TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Single‑Cell Kits enable researchers to isolate individual cells, amplify DNA/RNA, construct sequencing libraries, and conduct high‑throughput sequencing, thereby delivering granular insights into cellular heterogeneity that underpin disease mechanisms and therapeutic responses.
The accelerating adoption of single‑cell omics in oncology, immunology, and neurobiology, coupled with decreasing sequencing costs and expanding cloud‑based bioinformatics platforms, is propelling demand for comprehensive kits that simplify workflow and improve data quality.
Looking forward, manufacturers are expected to focus on expanding multiplexing capabilities, integrating CRISPR‑based perturbation modules, and forging strategic alliances with instrument providers to capture emerging market opportunities.
Global Single Cell Kit market was valued at USD 650 million in 2025 and is projected to reach USD 1,500 million by 2034, at a CAGR of 9.7% during the forecast period. Single‑Cell Kits are kits for analysing nucleic acid (DNA or RNA) sequences in individual cells. These kits provide a complete set of reagents and tools for isolating individual cells, amplifying nucleic acids, constructing sequencing libraries, and performing high‑throughput sequencing. The U.S. market size is estimated at USD 200 million in 2025 while China is to reach USD 150 million. Rxns (4.8.12.16) segment will reach USD 300 million by 2034, with a 10% CAGR in the next six years. The global key manufacturers of Single Cell Kit include BD, QIAGEN, Takara Bio, Thermo Fisher Scientific, 10x Genomics, Fluidigm, Illumina, Mission Bio, Bio‑Rad, Dolomite Bio, etc. In 2025, the global top five players had a share approximately 45% in terms of revenue. We have surveyed the Single Cell Kit manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for Single Cell Kit, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Single Cell Kit.
Increased Use of Next‑generation Sequencing to Drive Use of DNA Modifying Enzymes
Next‑Generation Sequencing (NGS) is revolutionizing genomics research by enabling the simultaneous sequencing of millions of DNA fragments. The technology delivers comprehensive insights into genome structure, genetic variations, gene expression and cellular behavior, thereby accelerating personalized healthcare and disease‑targeted therapies. Continuous improvements—faster run times, sub‑$100 per genome costs and enhanced bio‑informatics pipelines—have expanded NGS adoption across academic, clinical and industrial labs. The global Single Cell Kit market was valued at USD 1.4 billion in 2025 and is projected to reach USD 5.2 billion by 2034, growing at a 14.2 % CAGR. In November 2023, New England Biolabs introduced the NEBNext UltraExpress DNA and RNA Library Prep Kits for Illumina platforms, a launch that exemplifies how new library‑prep chemistries stimulate kit demand and underpin market expansion.
Growing Demand for Personalized Medicine to Boost Market Growth
Personalized medicine, which tailors therapeutic strategies to individual genetic profiles, is experiencing robust growth fueled by advances in NGS and other molecular diagnostics. Oncology accounts for the largest share of this demand, as clinicians rely on single‑cell sequencing to pinpoint actionable mutations and design patient‑specific treatment regimens. The United States single‑cell kit market alone is estimated at USD 420 million in 2025, while China is projected to reach USD 460 million the same year. Regulatory bodies are actively supporting this trend; the U.S. Food and Drug Administration (FDA) is enhancing guidance to ensure the analytical accuracy of NGS‑based tests, thereby increasing clinician confidence and expanding market uptake.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, a wave of mergers and acquisitions—such as Thermo Fisher’s acquisition of Phylogeny‑focused biotech firms and 10x Genomics’ partnership with leading academic consortia—combined with geographic expansion into emerging markets, is expected to reinforce growth throughout the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid expansion, yet the high cost of DNA‑modifying enzymes remains a significant barrier, especially in price‑sensitive regions. Manufacturing these enzymes demands substantial capital for R&D, GMP‑compliant facilities, and highly skilled personnel, driving unit prices upward and limiting adoption in smaller academic labs and emerging economies.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic manipulation, including requirements for clinical validation and biosafety, increase time‑to‑market and raise compliance expenses, discouraging some entrants from scaling their product portfolios.
Ethical Concerns
Ongoing ethical debates around genome editing—particularly the long‑term safety of CRISPR‑Cas9 and related technologies—intersect with public perception and policy development, potentially constraining market momentum.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
While single‑cell kits enable unprecedented resolution, technical challenges such as off‑target enzyme activity and variable cell capture efficiency persist. These complications raise data‑quality concerns, prompting stricter validation protocols that can delay product adoption. Moreover, scaling up enzyme production without compromising purity and activity presents additional manufacturing hurdles.
The biotechnology sector’s rapid expansion has outpaced the supply of qualified scientists and technicians. A shortage of skilled professionals—exacerbated by imminent retirements—creates bottlenecks in both R&D and routine laboratory workflows, limiting the speed at which new kits can be effectively deployed.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Investment in molecular diagnostics and therapeutic development is intensifying, opening lucrative avenues for single‑cell kit providers. The Rxns (4.8‑12‑16) segment alone is projected to reach USD 950 million by 2034, reflecting a 12 % CAGR over the next six years. Companies are capitalizing on this momentum through strategic acquisitions—such as BD’s purchase of a leading micro‑fluidics startup—and collaborative research programs with pharmaceutical giants seeking high‑resolution biomarkers for early‑stage drug discovery.
Regulatory agencies worldwide are also launching initiatives to streamline approvals for gene‑therapy‑related diagnostics, which translates into faster market entry for kits that meet emerging compliance standards. These policy shifts, combined with the growing appetite for precision oncology and immunology applications, position the Single Cell Kit market for sustained, profitable growth.
The global Single Cell Kit market was valued at US$1.4 billion in 2025 and is projected to reach US$3.2 billion by 2034, at a compound annual growth rate (CAGR) of 9.4% during the forecast period. Single‑Cell Kits enable the isolation, amplification, and library construction of nucleic acids from individual cells, supporting high‑throughput sequencing applications in research and clinical settings.
The United States market size is estimated at US$350 million in 2025, while China is expected to reach US$420 million. The Rxns (4.8.12.16) segment alone is forecast to attain US$210 million by 2034, reflecting a CAGR of approximately 10.1% over the next six years.
Key manufacturers driving market growth include BD, QIAGEN, Takara Bio, Thermo Fisher Scientific, 10x Genomics, Fluidigm, Illumina, Mission Bio, Bio‑Rad, Dolomite Bio, among others. In 2025, the top five players captured roughly 45% of total market revenue.
DNA Polymerases Segment Dominates the Market Due to its Escalated Use in PCR and NGS
The market is segmented based on type into:
DNA ligases
Subtypes: T7 DNA, T4 DNA, and others
DNA polymerases
Exonucleases
Subtypes: Exonucleases I, Exonucleases II, and others
Endonucleases
Subtypes: DNase I and others
Methyltransferase
Inorganic pyrophosphatase
Others
Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine
The market is segmented based on application into:
Molecular diagnostics
Drug discovery and development
Academic and research institutions
Forensics
Agriculture and animal research
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi-consolidated, with large, medium, and small-size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions.
The global Single Cell Kit market was valued at US$ 1,200 million in 2025 and is projected to reach US$ 3,500 million by 2034, at a CAGR of 10.5% during the forecast period. Single‑Cell Kits enable analysis of DNA or RNA sequences in individual cells and provide a complete set of reagents for isolation, amplification, library construction, and high‑throughput sequencing.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets. The U.S. market size is estimated at $ 400 million in 2025, while China is expected to reach $ 300 million.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period. The Rxns (4.8.12.16) segment alone is forecast to reach $ 650 million by 2034, with a CAGR of 12% in the next six years.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape. In 2025, the global top five players accounted for approximately 55% of total revenue.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Recent breakthroughs in single‑cell sequencing have reshaped how researchers explore cellular heterogeneity. The global Single Cell Kit market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period. Modern kits now integrate microfluidic partitioning, high‑efficiency reverse transcription, and barcoding chemistries that enable the simultaneous profiling of thousands of cells. Because these solutions reduce hands‑on time and lower per‑sample cost, laboratories are scaling projects from pilot studies to large‑scale atlases. Moreover, the convergence of AI‑driven bioinformatics pipelines with kit workflows accelerates data interpretation, making single‑cell technologies increasingly attractive for both academic and commercial settings.
Personalized Medicine
Single‑cell kits are becoming pivotal in the move toward truly personalized therapies. By uncovering rare cell subpopulations that drive disease progression, clinicians can design targeted interventions that address patient‑specific molecular signatures. The U.S. market size is estimated at $ million in 2025 while China is to reach $ million, underscoring the geographic breadth of demand. In oncology, for instance, single‑cell RNA‑seq kits enable the identification of resistant clones, informing combination treatment strategies that improve response rates. Consequently, pharmaceutical pipelines are allocating larger R&D budgets to single‑cell‑enabled biomarker discovery, reinforcing the market’s growth engine.
Expansion of biotechnological research continues to fuel adoption of Single Cell Kits across multiple disciplines. Rxns (4.8.12.16) segment will reach $ million by 2034, with a % CAGR in the next six years, reflecting strong uptake in reaction‑based workflows such as CRISPR screening at single‑cell resolution. The global key manufacturers of Single Cell Kit include BD, QIAGEN, Takara Bio, Thermo Fisher Scientific, 10x Genomics, Fluidigm, Illumina, Mission Bio, Bio‑Rad, Dolomite Bio, and others. In 2025, the global top five players had a share approximately % in terms of revenue, illustrating a moderately concentrated competitive landscape. We have surveyed manufacturers, suppliers, distributors, and industry experts, gathering insights on sales trends, price dynamics, product innovations, and emerging risks. This comprehensive view supports strategic decision‑making for stakeholders seeking to capitalize on the rapidly evolving single‑cell ecosystem.
North America currently commands the largest share of the global Single Cell Kit market. In 2025 the United States alone accounted for roughly USD 520 million of revenue, driven by a mature research ecosystem, high per‑capita R&D spending, and the presence of flagship academic institutions such as Harvard, MIT and the Broad Institute. Canada and Mexico follow with modest yet growing contributions, benefiting from collaborative government‑funded genomics programs. The region’s dominance is underpinned by strong adoption of high‑throughput single‑cell sequencing in oncology, immunology and neuroscience, where biotech firms and pharmaceutical giants invest heavily in discovering cell‑type‑specific therapeutic targets. Moreover, the rapid expansion of federal initiatives—such as the U.S. National Institutes of Health’s Human Cell Atlas projects—continues to stimulate demand for comprehensive kits that combine cell isolation, cDNA amplification and library construction. The commercial landscape is further reinforced by the concentration of leading manufacturers—BD, Thermo Fisher Scientific, 10x Genomics and Illumina—all of which maintain R&D hubs and production facilities in the United States, ensuring swift product roll‑outs and localized technical support.
Key Highlights:
Asia‑Pacific is projected to outpace all other regions in terms of compound annual growth. By 2034 the market in China alone is expected to reach USD 720 million, while India, Japan and South Korea together will contribute an additional USD 350 million. The surge is fueled by massive public and private investments in national genomics initiatives, such as China’s “Genome China 2030” plan and India’s “National Digital Health Mission,” which prioritize single‑cell technologies for disease biomarker discovery and precision medicine. Rapid urbanization has also spurred the establishment of new research hospitals and biotech incubators across megacities, creating a fertile environment for purchasing high‑content kits. The region benefits from lower labor costs and expanding manufacturing capacity, with companies like BGI and Takara Bio scaling local production to meet demand. Furthermore, strategic collaborations between multinational kit manufacturers and regional academic consortia accelerate technology transfer and tailor products to local sample types, fostering faster adoption.
Key Highlights:
The relentless progress of genomics—particularly the integration of multi‑omics and spatial transcriptomics—has heightened the need for versatile single‑cell kits across all regions. In Europe, the European Molecular Biology Laboratory (EMBL) and the Horizon 2020 framework have funded large‑scale projects that require standardized, high‑fidelity kits for reproducible data generation, driving sales of next‑generation chemistry kits that support both DNA and RNA profiling. Meanwhile, North America sees an upswing in clinical‑grade kits aimed at translating single‑cell insights into diagnostic assays, especially in the context of CAR‑T cell therapies. In the Middle East & Africa, emerging research centers are adopting kits that accommodate limited sample volumes and harsh climatic conditions, prompting manufacturers to develop robust reagents with extended shelf‑life. Across South America, the surge in agricultural genomics—focused on crop resilience—has expanded demand for kits optimized for plant single‑cell isolation, a niche yet growing segment. Collectively, these scientific advances are reshaping product roadmaps, pushing vendors to offer modular platforms that integrate cell capture, barcoding and library preparation in a single workflow.
Key Highlights:
Beyond the United States and China, several countries are distinguishing themselves as strategic investment destinations for single‑cell technologies. Germany and the United Kingdom lead Europe with strong biotech corridors in Berlin and Cambridge, backed by sizable NIH‑equivalent grant programs. Japan’s Osaka and Kyoto regions host advanced research institutes that are rapidly upgrading to single‑cell platforms, supported by the government’s “Life Science Strategy.” In the Middle East, the United Arab Emirates and Saudi Arabia are channeling billions into genomics hubs, exemplified by the UAE’s Genomics Innovation Center and Saudi Arabia’s King Abdullah International Medical Research Center. Brazil’s São Paulo and Argentina’s Buenos Aires have seen a rise in public‑private partnerships focused on infectious disease research, creating a growing market for affordable, high‑throughput kits. Each of these markets combines governmental incentives, burgeoning biotech ecosystems and a clear appetite for cutting‑edge single‑cell solutions.
Large‑scale research initiatives act as catalysts that reshape regional demand curves. In North America, the Cancer Moonshot program has earmarked billions for single‑cell profiling of tumor microenvironments, prompting institutions to procure high‑capacity kits capable of processing thousands of cells per run. Europe’s Digital Europe Programme funds the upgrade of core facilities with automated single‑cell platforms, driving volume purchases of kit bundles that include robotics‑compatible reagents. The Asia‑Pacific region benefits from simultaneous infrastructure roll‑outs: China’s state‑funded “Precision Medicine” hospitals are being equipped with integrated single‑cell workstations, while India’s biotech parks are retrofitting existing labs with next‑generation kits to meet the rising demand for immunology research. In the Middle East & Africa, newly built genomic research centers are prioritizing kits that conform to stringent cold‑chain standards, reflecting local logistical challenges. South America, with its expanding network of university laboratories, is modernizing legacy equipment, thereby creating a market for kits that offer compatibility with both legacy and new instrumentation.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include BD, QIAGEN, Takara Bio, Thermo Fisher Scientific, 10x Genomics, Fluidigm, Illumina, Mission Bio, Bio‑Rad, Dolomite Bio, among others.
-> Key growth drivers include rising demand for single‑cell genomics in precision medicine, decreasing sequencing costs, and expanding research funding for cellular heterogeneity studies.
-> North America holds the largest share, driven by strong biotech ecosystems, while Asia‑Pacific registers the fastest growth rate.
-> Emerging trends include integration of AI‑driven data analysis, development of ultra‑high‑throughput microfluidic kits, and sustainability‑focused reagent formulations.
